$VSTM

Paterson Dan sold $87K of VSTM

Paterson Dan (President and CEO) sold 20,871 shares of Verastem, Inc. (VSTM) at $4.18 on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Paterson Dan
Published Jun 24, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VSTM
Neutral
high confidence
Mentioned
$VSTM
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VSTMNeutralLow
01

Why it matters

The CEO’s open-market sale reduces insider holdings but does not, by itself, indicate a change in company fundamentals given the stated 10b5-1 plan.

02

Market read

Primarily a sentiment/positioning datapoint; likely insufficient alone to drive a sustained repricing without accompanying operational or financial news.

03

What to watch

Traders may overreact to insider sales; the key differentiator here is the pre-arranged 10b5-1 structure, which usually lowers the signal-to-noise.

Relevance 2/10Novelty 4/10Timing: after-hours/filing timestamp 2026-06-24; reflects 2026-06-22 sale

Background

The article is a SEC Form 4 insider transaction disclosure for Verastem, Inc. (VSTM).

Company-level read

Ticker impact

$VSTMNeutralHigh confidence
Context

Verastem CEO Paterson Dan sold 20,871 shares at $4.18/share under a 10b5-1 plan, disclosed via Form 4 on 2026-06-24.

Expected impact

Low near-term impact; any reaction is likely muted and short-lived unless paired with other new company-specific catalysts.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, which generally reduces interpretive weight for immediate fundamentals.

Market effects

No clear sector read-through; this is company-specific insider liquidity rather than a sector/regulatory shift.

None.

None.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may be more about scheduled diversification/liquidity than bearish expectations.

Key entities

  • Verastem, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Paterson Dan

    President and CEO who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVCRLowAI 8/10

Novocure partners with Verastem on pancreatic cancer trial

Novocure (NVCR) and Verastem Oncology (VSTM) partner to test Tumor Treating Fields therapy with VS-7375 for pancreatic cancer. Trial to start in 2027, focusing on safety and tolerability in 25 patients. Novocure will fund and manage the trial, while Verastem supplies the drug. The treatment aims to combine chemotherapy, VS-7375, and Tumor Treating Fields. Pancreatic cancer has a low survival rate and limited treatment options.

$NVCRLowAI 8/10

A planned trial will test electric-field therapy with chemotherapy and an experimental drug.

Novocure (NVCR) and Verastem Oncology plan a clinical trial to evaluate Tumor Treating Fields (TTFields) therapy with chemotherapy and Verastem’s experimental drug VS-7375 for locally advanced pancreatic cancer. The trial, expected to start in 2027, will assess safety and preliminary efficacy in about 25 patients. Novocure will manage and fund the trial, while Verastem will supply the drug. Both companies believe the combination could offer a new treatment approach for this challenging cancer.

$VSTMHighAI 8/10

Wainwright reiterates Verastem stock rating on China trial data

H.C. Wainwright reiterated a Buy rating and $18.00 price target for Verastem (VSTM) after positive clinical trial data from China. The stock rose 10% last week to $9.23, up 46% in six months. GenFleet's data showed promising results for GFH375, the same molecule as Verastem's VS-7375, in colorectal and pancreatic cancer trials. Analysts maintain a strong buy consensus with targets ranging from $12 to $24.